Roughly two-thirds of the 150 top-selling prescription drugs sold in 2020 had low “added clinical benefit” compared to existing drugs.

Among the drugs with low added benefit: Gammagard Liquid, Yervoy, Ibrance, Odefsey, Entyvio, Genvoya, and Mavyret.

Among the drugs with high added benefit: Ocrevus, Opdivo, Keytruda, Neulasta, and Hemlibra.

Companies spent a bigger fraction of their 2020 ad dollars on direct-to-consumer ads for the drugs with low added benefit than for the drugs with high added benefit.

(Those added-benefit ratings come from France or Canada. The U.S. doesn’t rate drug benefits.)

What to do

Seen an impressive drug ad on TV? Don’t assume that it’s your best option. 

More on deceptive marketing